By Benjamin Chiou
Date: Thursday 27 Jun 2024
(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for the company's Arexvy product.
Arexvy is currently approved by the Food and Drug Administration for the prevention...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news